Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance
Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance in
patients with chronic myelogenous leukemia. Many mutations favor active kinase …
patients with chronic myelogenous leukemia. Many mutations favor active kinase …
[HTML][HTML] Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance
M Azam, V Nardi, WC Shakespeare… - Proceedings of the …, 2006 - ncbi.nlm.nih.gov
Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance in
patients with chronic myelogenous leukemia. Many mutations favor active kinase …
patients with chronic myelogenous leukemia. Many mutations favor active kinase …
Activity of Dual SRC-ABL Inhibitors Highlights the Role of BCR/ABL Kinase Dynamics in Drug Resistance
M Azam, V Nardi, WC Shakespeare… - Proceedings of the …, 2006 - JSTOR
Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance in
patients with chronic myelogenous leukemia. Many mutations favor active kinase …
patients with chronic myelogenous leukemia. Many mutations favor active kinase …
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
M Azam, V Nardi, WC Shakespeare… - Proceedings of the …, 2006 - europepmc.org
Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance in
patients with chronic myelogenous leukemia. Many mutations favor active kinase …
patients with chronic myelogenous leukemia. Many mutations favor active kinase …
[PDF][PDF] Activity of dual SRC-ABL inhibitors highlights the role of BCR ABL kinase dynamics in drug resistance
M Azam, V Nardi, WC Shakespeare, CA Metcalf III… - PNAS, 2006 - academia.edu
Results Kinase-Activating IMR BCRABL Variants Are Sensitive to AP23464 and PD166326.
AP23464 and PD166326 are synthetic small-molecule, ATP-competitive dual-specificity …
AP23464 and PD166326 are synthetic small-molecule, ATP-competitive dual-specificity …
[PDF][PDF] Activity of dual SRC-ABL inhibitors highlights the role of BCR ABL kinase dynamics in drug resistance
M Azam, V Nardi, WC Shakespeare, CA Metcalf III… - PNAS, 2006 - researchgate.net
PD166326. AP23464 and PD166326 are synthetic small-molecule, ATP-competitive dual-
specificity SRCABL kinase inhibitors (Fig. 1A). AP23464 and PD166326 inhibited the …
specificity SRCABL kinase inhibitors (Fig. 1A). AP23464 and PD166326 inhibited the …
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance
M Azam, V Nardi, WC Shakespeare… - Proceedings of the …, 2006 - ui.adsabs.harvard.edu
Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance in
patients with chronic myelogenous leukemia. Many mutations favor active kinase …
patients with chronic myelogenous leukemia. Many mutations favor active kinase …
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance
M Azam, V Nardi, WC Shakespeare… - Proceedings of the …, 2006 - pubmed.ncbi.nlm.nih.gov
Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance in
patients with chronic myelogenous leukemia. Many mutations favor active kinase …
patients with chronic myelogenous leukemia. Many mutations favor active kinase …
[引用][C] Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance
M AZAM - Proc Natl Acad Sci USA, 2006 - cir.nii.ac.jp
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug
resistance | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
resistance | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
[PDF][PDF] Activity of dual SRC-ABL inhibitors highlights the role of BCR ABL kinase dynamics in drug resistance
M Azam, V Nardi, WC Shakespeare, CA Metcalf III… - PNAS, 2006 - researchgate.net
PD166326. AP23464 and PD166326 are synthetic small-molecule, ATP-competitive dual-
specificity SRCABL kinase inhibitors (Fig. 1A). AP23464 and PD166326 inhibited the …
specificity SRCABL kinase inhibitors (Fig. 1A). AP23464 and PD166326 inhibited the …